Skip to main content

Table 3 IRR of time to first AE stratified by diagnostic group. Poisson regression model, crude, and adjusted

From: Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

Variable

RA

PsA

AS

Crude IRR (CI95%)

p

Adjusted IRR (CI95%)

p

Crude IRR (CI95%)

p

Adjusted IRR (CI95%)

p

Crude IRR (CI95%)

p

Adjusted IRR (CI95%)

p

Age (ref. adults)*

 Young

1.16 (0.62–2.17)

0.639

1.20 (0.62–2.33)

0.585

0.47 (0.19–1.13)

0.091

0.49 (0.18–1.31)

0.153

0.85 (0.52–1.39)

0.53

1.13 (0.67–1.90)

0.65

 Elderly

1.59 (1.30–1.95)

< 0.001

1.55 (1.23–1.95)

< 0.001

1.60 (1.08–2.36)

0.019

1.25 (0.89–1.97)

0.336

1.36 (0.73–2.56)

0.336

1.34 (0.63–2.86)

0.446

 Very Elderly

1.77 (1.24–2.52)

0.002

1.76 (1.18–2.61)

0.005

4.35 (1.40–13.57)

0.011

4.40 (1.30–14.87)

0.017

5.94 (1.48–23.84)

0.012

2.86 (0.65–12.59)

0.165

Women

1.00 (0.83–1.20)

0.99

1.14 (0.93–1.41)

0.209

1.72 (1.40–2.11)

< 0.001

1.60 (1.26–2.04)

< 0.001

1.35 (1.07–1.70)

0.012

1.42 (1.09–1.85)

0.01

Treatments

 Corticosteroids

1.01 (0.86–1.18)

0.913

  

1.73 (1.37–2.18)

< 0.001

1.48 (1.13–1.93)

0.004

1.59 (1.17–2.16)

0.003

1.35 (0.95–1.91)

0.098

 MTX

1.26 (1.07–1.47)

0.004

1.25 (1.07–1.47)

0.006

1.34 (1.07–1.69)

0.012

1.31 (1.01–1.68)

0.041

1.78 (1.36–2.31)

< 0.001

1.56 (1.13–2.14)

0.006

 Other

1.08 (0.93–1.25)

0.325

  

1.37 (1.09–1.72)

0.008

1.43 (1.09–1.88)

0.01

1.02 (0.76–1.36)

0.897

  

Smoking (ref. No)

 Smoker/past smoker

1.29 (1.09–1.53)

0.004

1.28 (1.05–1.57)

0.015

1.36 (1.07–1.73)

0.012

1.09 (0.81–1.46)

0.578

1.26 (1.01–1.58)

0.042

1.18 (0.90–1.54)

0.234

Comorbidities

 Charlson Index

1.12 (1.05–1.20)

0.001

1.08 (1.00–1.17)

0.048

1.13 (1.00–1.29)

0.056

1.09 (0.93–1.29)

0.293

1.26 (1.07–1.47)

0.005

1.28 (1.06–1.54)

0.01

Time&

1.00 (0.99–1.01)

0.818

  

1.01 (0.99–1.03)

0.399

  

1.01 (1.00–1.03)

0.008

1.02 (1.01–1.03)

0.004

  1. *Age at the beginning of biological treatment
  2. &Time of disease duration
  3. AS ankylosing spondylitis, DMARDs disease-modifying antirheumatic drugs, IRR incidence rate ratio, MTX methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitor